Publications Update # 109
Everyones the hero of their own story, management of contralateral groin in vulvar cancer (with video), non-myoinvasive uterine papillary serous carcinoma with positive washings.
Shitanshu Uppal
Publications Update # 108
An article on insomnia, question of the week (C. Diff testing), fertility preservation outcomes in CAH/G1EC, immunotherapy in transplant patients, and FDA review of PARP inhibitors.
Publications Update # 107
A discussion on how to cure loneliness in the US, Phase 2 trial - Most Circuit - Ipi/Nivo in clear cell cancer, camrelizumab and Famitinb in cervical cancer, impact of prior radiation on immunotherapy drugs, and HRT in young patients.
Camrelizumab and Famitinib in Cervical Cancer - Phase 2 Trial
Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.
Publications Update # 106
MAPK/FAK Clamp - RAMP 201 Avutomentinib and Defactinib in Low Grade Ovarian, IP chemotherapy question, ROSELLA Trial and PROFECTA-II Trial, Palliative Oophorectomy in gastric cancers
GOG 3073/ENGOT-72: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA)
Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.
Publications Update # 105
Making magic with Brad Meltzer, venous thromboembolism during ambulatory chemotherapy in endometrial cancer (including the NCCN and ASCO guidelines), IMRT in vulvar cancer, and hypofractionated adjuvant radiation in cervical cancer patients.
Publications Update # 104
New Episode of GYOEDU Podcast, ASCO abstracts - Challenge trial, TRUST trial, cytoxan+Avastin vs. cytoxan+Avastin+Pembrolizumab, Menopause management with Elinzatenant, and a review of cancer of unknown primary site.
Publications Update # 103
MIS in cervical cancer in SHAPE trial-eligible patients, pragmatic testing with IHC rather to replace the PROMISE algorithm and two questions about PFT and vulvar cancer groin management.